The utilization of nanomaterials in the biological and medical field is quickly progressing,
particularly in areas where traditional diagnostics and treatment approaches have limited …

Increasing attention has been paid to the diseases of central nervous system (CNS). The
penetration efficiency of most CNS drugs into the brain parenchyma is rather limited due to …

The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted
nanoparticles are engineered to reduce non-productive distribution while improving …

The central nervous system (CNS) poses a unique challenge for drug delivery. The blood–
brain barrier significantly hinders the passage of systemically delivered therapeutics and the …

Over the last decade, significant progress has been made in the field of drug delivery. The
advent of engineered nanoparticles has allowed us to circumvent the initial limitations to …

Glioblastoma multiforme, a grade IV glioma, is the most frequently occurring and invasive
primary tumor of the central nervous system, which causes about 4% of cancer-associated …

With an aging population that has been increasing in recent years, the need for the
development of therapeutic approaches for treatment of neurodegenerative disorders (ND) …

Current therapy for glioblastoma multiforme is insufficient, with nearly universal recurrence.
Available drug therapies are unsuccessful because they fail to penetrate through the region …

Convection-enhanced delivery (CED) is a bulk flow–driven process. Its properties permit
direct, homogeneous, targeted perfusion of CNS regions with putative therapeutics while …

Creating a cellular model of Alzheimer's disease (AD) that accurately recapitulates disease
pathology has been a longstanding challenge. Recent studies showed that human AD …